Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 6/20 | 0.33 |
| ▸ | EIF2AK3 | Q9NZJ5 | 6/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563419 | 0.92 | MAP2K1 (0.68) | MAP2K1MEN1KMT2ATDP1BRAF | |
| SCHEMBL2568336 | 0.89 | MAP2K1 (0.56) | MAP2K1MEN1KMT2ATDP1BRAF | |
| SCHEMBL2568085 | 0.88 | MAP2K1 (0.51) | MAP2K1BRAFEIF2AK3MAPK14 | |
| SCHEMBL14199457 | 0.86 | MAP2K1 (0.59) | MAP2K1MEN1KMT2ATDP1BRAF | |
| SCHEMBL14300141 | 0.86 | MAP2K1 (0.55) | MAP2K1BRAFEIF2AK3MAPK14 | |
| SCHEMBL2565128 | 0.86 | MAP2K1 (0.55) | MAP2K1MAPK14 | |
| SCHEMBL2568253 | 0.86 | MAP2K1 (0.55) | MAP2K1MEN1KMT2ATDP1BRAF | |
| SCHEMBL2565085 | 0.79 | MAP2K1 (0.53) | MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL2567448 | 0.79 | MAP2K1 (0.58) | MAP2K1BRAFEIF2AK3 | |
| SCHEMBL2565900 | 0.79 | MAP2K1 (0.58) | MAP2K1BRAFEIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069354-B1 | Aza-benzofuranyl compounds and methods of use | GENENTECH INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | MAP2K1 10/4885MEN1 2716/4885KMT2A 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.